Krishna Institute of Medical Sciences (KIMS) reported contrasting financial results for the June quarter, with consolidated net profit falling 47.2% year-on-year to ₹41.50 crore compared to ₹78.60 crore in the same period last year. Despite the profit decline, the hospital chain demonstrated strong operational growth with revenue from operations rising 35.3% to ₹1,180 crore from ₹872 crore in the previous year. According to the latest unaudited financial results approved by the Board of Directors on August 3, 2026, total income reached ₹1,196 crore, marking a 36.1% increase year-on-year and 10.3% rise quarter-on-quarter. EBITDA stood at ₹220 crore with margins contracting to 18.94% from 22.10% a year ago, reflecting the capital-intensive nature of KIMS's expansion strategy.
KIMS significantly expanded its operational footprint during the quarter, with total bed capacity increasing to over 8,300 beds across 26 hospitals as of June 30, 2026, compared with 6,464 beds at the end of March and 5,499 beds a year earlier. As reported by CNBC TV18, Chairman and Managing Director B. Bhaskara Rao highlighted that the company began FY27 on a strong note with the addition of a new hospital in Palakkad, Kerala. The group's patient volumes were the primary driver of top-line growth, with inpatient admissions rising 26.6% year-on-year to 72,493 and outpatient visits increasing 28.5% to 658,617. Average Revenue Per Occupied Bed (ARPOB) increased 9.7% year-on-year to ₹47,200, while Average Revenue Per Patient (ARPP) rose 6.8% year-on-year to ₹1,63,573, though it declined 3.8% quarter-on-quarter. With nearly 1,300 beds in expansion pipeline, the company has strong multi-year growth visibility ahead.
The company has strategically expanded its asset-light growth strategy by signing Operations & Management (O&M) and Call Option Agreements with Golden Lan and Sarwottam Healthcare, marking further steps in its asset-light expansion approach. These agreements are consistent with KIMS's strategy of managing hospital facilities under O&M arrangements while retaining the option to acquire ownership stakes at a future date. The addition of these partnerships is expected to broaden the group's geographic footprint and contribute to revenue ramp-up over time. The company has also utilized part of the ₹1,500 crore raised through a qualified institutional placement (QIP) completed in FY26, with the remaining funds temporarily invested in mutual funds and placed in a monitoring account.
Despite mixed financial results, KIMS demonstrated strong clinical performance with significant milestones across its network. Telangana remained the largest revenue contributor, while newer markets showed early traction with Kerala units generating revenue with an EBITDA margin of 9.7% and Maharashtra units posting an EBITDA margin of 7.5%. The company achieved several clinical firsts, including KIMS Secunderabad completing 10,000 brain tumour surgeries, KIMS Kingsway Nagpur performing its first allogeneic bone marrow transplant and the first robotic Perceval plus valve implantation in Asia Pacific, and KIMS Saveera Anantapur achieving the region's first Transcatheter Aortic Valve Replacement (TAVR). Profit before tax (PBT) fell 50.2% year-on-year to ₹57 crore, impacted by statutory adjustments related to new Labour Codes and fair valuation losses on call options, with basic earnings per share (EPS) degrowing by 47.2% to ₹1.04.
